Mistry, P. K., Balwani, M., Baris, H. N., Turkia, H. B., Burrow, T. A., Charrow, J., … Cox, T. M. (2019). Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells Mol Dis, 77, 101–102. https://doi.org/10.1016/j.bcmd.2019.04.003

Mistry, Pramod K., Manisha Balwani, Hagit N. Baris, Hadhami Ben Turkia, T Andrew Burrow, Joel Charrow, Gerald F. Cox, et al. “Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.” Blood Cells Mol Dis 77 (July 2019): 101–2. https://doi.org/10.1016/j.bcmd.2019.04.003.

Mistry PK, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, et al. Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells Mol Dis. 2019 Jul;77:101–2.

Mistry, Pramod K., et al. “Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.” Blood Cells Mol Dis, vol. 77, July 2019, pp. 101–02. Pubmed, doi:10.1016/j.bcmd.2019.04.003.

Mistry PK, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, Cox GF, Danda S, Dragosky M, Drelichman G, El-Beshlawy A, Fraga C, Freisens S, Gaemers S, Hadjiev E, Kishnani PS, Lukina E, Maison-Blanche P, Martins AM, Pastores G, Petakov M, Peterschmitt MJ, Rosenbaum H, Rosenbloom B, Underhill LH, Cox TM. Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells Mol Dis. 2019 Jul;77:101–102.